CClinicalTrials.gg
CompletedNCT05962034Updated Jul 27, 2026

Thromboxane Function in Women With Endometriosis

A Phase 4 interventional study of Aspirin and Placebo in Endometriosis, sponsored by Penn State University. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Penn State University · Phase 4, Interventional, and Basic science

Phase
Phase 4
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to compare neurovascular regulation in women with endometriosis and healthy women. The main questions it aims to answer are:

  • Do women with endometriosis have greater blood pressure and pain responses to a stimulus than healthy women?
  • Do women with endometriosis have greater platelet activity than healthy women?

Participants will take aspirin and/or placebo and will:

  • perform hand grip exercise and cold pressor tests
  • undergo iontophoresis and blood draw

Researchers will compare women with and without endometriosis to see if there is a difference in neurovascular regulation.

Read the detailed description

Cardiovascular disease (CVD) is the leading cause of death worldwide. Endometriosis is an independent risk factor for CVD that affects an estimated one in ten women in the world. Endometriosis is a gynecologic condition characterized by invasive extrauterine endometriotic lesions, chronic pain, and systemic inflammation. The expression of thromboxane A2 (TxA2), a product of the inflammatory cyclooxygenase pathway, is upregulated in endometriotic lesions. In the vasculature, TxA2 blocks vasodilation, and induces vasoconstriction. TxA2 diffuses across the innermost layer of cells in the blood vessels, the endothelium, to act directly on its receptors in the vascular smooth muscle. It also inhibits endothelial nitric oxide synthase, thereby decreasing nitric oxide (NO)-mediated vasodilation --endothelial dysfunction which is regarded as a critical early event in the development of atherosclerosis and overt cardiovascular disease. Women with endometriosis demonstrate marked endothelial dysfunction compared with healthy controls, but the potential role of TxA2 and its receptors (TP) in this dysfunction have not been investigated. Furthermore, TP play a key role in sensitizing the sensory afferent nerve fibers in pre-clinical models of cardiovascular disease, leading to an exaggerated blood pressure responses to sympathoexcitatory maneuvers including the exercise pressor reflex. The exercise pressor reflex is the reflex increase in blood pressure in response to the mechanical and metabolic stimuli of exercise. The exaggeration of this reflex response is a strong predictor of major adverse cardiovascular events in cardiovascular disease patients. However, the reflex response to sympathoexcitatory maneuvers has not been characterized in women with endometriosis. Furthermore, TxA2 is a key component in the clotting cascade. An increased production of TxA2 in the platelet cells of women with endometriosis indicates altered platelet function. However, platelet activity in women with endometriosis has not been characterized.

02

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
  • Aspirin
03

In context

Endometriosis

901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.

This study's enrollment of 21 is below the median of 64 across 525 interventional studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Penn State University is the lead sponsor of 263 studies on the registry; 51 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 10 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Born with a uterus
  • 18-45 years old
  • With and without endometriosis

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or breastfeeding
  • Diagnosed cardiovascular disease
  • BMI over 35
  • Nicotine use (e.g., smoking, chewing tobacco, vaping, etc.)
  • Currently using hormone replacement therapy (or have used within previous 6 months)
  • Known skin allergies or current rash, skin disease, disorders of pigmentation
  • Diabetes
  • Renal disease, renal artery stenosis, renal impairment
  • Liver disease
  • Stage II Hypertension (blood pressure >140/>90 mmHg)
  • Hypotension (blood pressure \< 90/60 mmHg)
  • Raynaud's syndrome
  • Any current medications which could conceivably alter cardiovascular responses (e.g. antihypertension medication, diuretic, digoxin)
  • Allergy or hypersensitivity to investigational agents
  • Immunosuppressed/immunocompromised
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Aspirin

    one dose of aspirin

    Drug: Aspirin

  • Placebo comparator
    Placebo

    Placebo pill

    Other: Placebo

Interventions

  • DrugAspirin

    650 mg aspirin (Acetylsalicylic acid)

  • OtherPlacebo

    placebo capsule

06

What researchers measure

Primary outcomes

  1. blood pressure

    change in blood pressure from baseline to maximum

    Time frame: 1 day

  2. heart rate

    change in heart rate from baseline to maximum

    Time frame: 1 day

  3. pain scale

    pain scale rating in response to testing

    Time frame: 1 day

  4. skin blood flow

    change in skin blood flow from baseline to maximum

    Time frame: 1 day

07

Study locations

1 site
  • Noll Laboratory
    University Park, Pennsylvania 16802, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05962034
Lead sponsor
Penn State University
Responsible party
Lacy Alexander (Professor of Kinesiology, Penn State University) — Principal investigator
First posted
Jul 27, 2023
Start date
Jan 1, 2024
Primary completion
Jul 1, 2026
Completion
Jul 23, 2026
Last update
Jul 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion